Clinical Dilemmas in Primary Liver Cancer
John Wiley & Sons Inc (Hersteller)
978-1-119-96220-5 (ISBN)
- Keine Verlagsinformationen verfügbar
- Artikel merken
Clinical Dilemmas in Liver Cancer follows the successful format of the other books in the Clinical Dilemmas series, with each chapter focused on a specific dilemma, or issue facing doctors in their day-to-day job, and providing them with practical clinical information and help to better assessment and treat their patients - in this case patients suffering from liver cancer, the third commonest cancer in terms of mortality worldwide. Chapters feature up-to-date information on the basic mechanisms, epidemiological risk factors, screening and surveillance strategies, diagnosis and treatment. It is an extremely practical and clinically-orientated book, and as most patients around the world present with advanced disease, a main focus is on the most recent advances allowing early diagnosis and use of locoregional and systemic therapy, surgery, transplantation and combination therapies. Each chapter is authored by an international expert in the relevant area.
Professor Roger Williams CBE, runs the Institute of Hepatology at UCL, and is a twice former president of EASL. He has authored an incredible 2100 journal articles. Despite advancing years, he is still actively involved in clinical research-340 articles in the past ten years, and analysis by ISI shows him to be one of the most influential researchers in his field. The award of a CBE for services to medicine recognised his major contribution to the study of liver disorders over 25 years including leading the team who performed the first ever liver transplant in the UK. Prof Williams has had many awards, medals, honorary fellowships, and in 2006 was included by HRH The Queen in a celebration at Buckingham Palace to honour those who continue to contribute to public service beyond the age of 65yrs. He was made a Fellow of King's College London in 1992 and an Honorary Fellowship from UCL was conferred on him in 2008, in recognition of his distinguished career and outstanding service to UCL. Professor Simon Taylor-Robinson joined the Department of Medicine at Imperial College London in 1997, having previously been Senior Registrar in Gastroenterology and Hepatology at Hammersmith Hospital. He was awarded the Sir Francis Avery Jones Gold Medal by the British Society of Gastroenterology in 1999 and the Young Investigator Award of the Liver Section of the European Gastroenterology Association in 1997. He is currently Director of the Imperial Clinical Research Facility at St Mary's Hospital, London.
List of Contributors. Preface. Part 1: Learning from a Worldwide Perspective. 1 Are patterns and prevalence changing? (Hashem B. El-Serag). 2 Why is the tumour different in Africa? (Nimzing G. Ladep). 3 Control by vaccination: Asian and Taiwan experience (Jia-Horng Kao). 4 The view from the UK (Shahid A. Khan, Mireille B. Toledano, Abigail Zabron, Mehtan Ahmed, and Simon D. Taylor-Robinson). 5 The view from the United States (Hitoshi Maruyama and Arun J. Sanyal). 6 New challenges of NAFLD and HIV epidemics (Quentin M. Anstee and Janice Main). Part 2: Influence of Tumour Characteristics. 7 Controversies in Pathology (Tania Roskams). 8 Not to forget the unusual tumour (Bernard C. Portmann). 9 What can be learned from molecular diagnostic techniques and genetic signatures? (Tariq Moatter and Saeed Hamid). Part 3: Complexities of Patient Assessment and Scoring Systems. 10 Looking after the liver as well as the tumour (Roger Williams). 11 Comparative performances of staging systems for hepatocellular cancer: Early HCC considerations (Peter D. Peng, Timothy M. Pawlik). 12 Rival scoring systems: Do they offer more? (Angelo Sangiovanni and Massimo Colombo). 13 Is it possible to detect early lesions effectively? (Ryota Masuzaki and Masao Omata). 14 What is the value of country based surveillance programmes? (Peter Ott). Part 4: Choice of Radiological Diagnostic Technique. 15 Computed tomography or magnetic resonance imaging for the diagnosis of hepatocellular carcinoma (Wladyslaw Gedroyc). 16 Is Microbubble ultrasound useful? (Adrian Lim). 17 Value of PET scanning (Tara Barwick, Imene Zerizer, and Adil Al-Nahhas). Part 5: Can Treatment be Tailored to the Patient? 18 Who could benefit from chemoembolisation? (Gisele N'Kontchou, Olivier Seror, and Michel Beaugrand). 19 Are drug eluting beads (DEB) worth using? (C. N. Hacking and Pradesh Kumar). 20 What's the future of image-guided radiofrequency ablation for hepatocellular carcinoma? (Riccardo Lencioni). 21 Alternative ablation techniques for hepatocellular carcinoma (John Karani). 22 Justification for Sorafenib and chemotherapy (Philip J. Johnson). 23 When to consider surgery? (Emmanuel Melloul, Mickael Lesurtel, and Pierre-Alain Clavien). 24 Transplant considerations (Myron Schwartz). Part 6: What Does the Future Hold? 25 Dipstick markers for diagnosis: Feasible or not? (Mohamed I. F. Shariff and Simon D. Taylor-Robinson). 26 Targeted gene therapy for hepatocellular carcinoma (HCC): A reality? (Christopher Binny, Marco Della Peruta, and Amit C. Nathwani). 27 Is immune modulation a possibility? (Tim F. Greten and Firouzeh Korangy). 28 Systemic therapy for hepatocellular carcinoma: Future directions (Daniel H. Palmer, Matthew Cramp).
| Verlagsort | New York |
|---|---|
| Sprache | englisch |
| Maße | 150 x 250 mm |
| Gewicht | 666 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hepatologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| ISBN-10 | 1-119-96220-X / 111996220X |
| ISBN-13 | 978-1-119-96220-5 / 9781119962205 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
